UBS Group
SHPH icon

UBS Group’s Shuttle Pharmaceuticals SHPH Stock Holding History

UBS Group’s Portfolio SHPH Stock Details SHPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-567
Closed -$3.85K – 10975
2026
Q1 		$3.85K Sell
567
-628
-53% -$8.51K ﹤0.01% 9024
2025
Q4 		$21.5K Buy
1,195
+1,194
+119,400% +$30.5K ﹤0.01% 7733
2025
Q3 		$28 Sell
1
-336
-100% -$12.6K ﹤0.01% 10087
2025
Q2 		$12.7K Buy
+337
New +$20.2K ﹤0.01% 8730
2025
Q1 		– Sell
-131
Closed -$28.2K – 10675
2024
Q4 		$28.2K Buy
+131
New +$34.1K ﹤0.01% 7651
2024
Q2 		– Sell
-1
Closed -$455 – 10027
2024
Q1 		$455 Buy
+1
New +$842 ﹤0.01% 8549
2023
Q1 		– Hold
0
– -$951 – 10291
2022
Q4 		– Sell
-17
Closed -$82.6K – 10019
2022
Q3 		$156K Buy
+17
New +$692K ﹤0.01% 5322

Other funds holding SHPH

HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
KFA
Kelleher Financial Advisors New York $705M AUM 16.14% 1-Year Est. Return

UBS Group's SHPH Position: Q2 2026 in Review

UBS Group sold out of Shuttle Pharmaceuticals (SHPH) in Q2 2026, closing a stake of 567 shares — an estimated $3.85K sold.

UBS Group first reported a position in SHPH in Q3 2022 and held it in 7 quarters. The position peaked at $156K in Q3 2022. 5 funds tracked by Wall St. Rank hold SHPH as of Q2 2026.

  • UBS Group reported no remaining Shuttle Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • UBS Group sold 567 Shuttle Pharmaceuticals shares in Q2 2026, an estimated $3.85K.
  • UBS Group first reported a position in Shuttle Pharmaceuticals in Q3 2022 and held it in 7 quarters.
  • UBS Group's Shuttle Pharmaceuticals position peaked at $156K in Q3 2022.
  • 5 funds tracked by Wall St. Rank held Shuttle Pharmaceuticals as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.